Fundraising Fox
/Companies
Sign in

bioAffinity Technologies

NASDAQ: BIAF

San Anonio, US · Founded 2014 · Delaware corporation

Find your way into bioAffinity Technologies

248 people in our graph share verified history with the bioAffinity Technologies team — schools, employers, funds. One of them is your warm intro.

Ed Byrneunlockedknows Michael Dougherty · together at FileStack (overlapped)
×11knows the team · via Russell Investments

bioAffinity Technologies develops noninvasive laboratory diagnostic tests that use flow cytometry and machine learning analysis to detect early-stage lung cancer and other lung diseases from sputum samples. The company's lead product, CyPath® Lung, is offered through its subsidiary PPLS, a CAP-accredited clinical laboratory, and serves physicians evaluating patients at high risk for lung cancer.

Biotech

Founders & leadership

bioAffinity Technologies was founded in 2014 by Maria Zannes.

MZMaria Zannes
Maria ZannesFounder · Chief Executive Officer, President and Director at bioAffinity Technologies, Inc.Maria Zannes holds a B.A. in Journalism from the University of New Mexico and a J.D. from the University of Puget Sound; she brings over three decades of executive management experience across the medical, environmental, and energy sectors, including prior roles as founder of The Zannes Firm, President of the Energy Recovery Council, and project manager at Wheelabrator Technologies, and is licensed to practice law in New Mexico.
VR
Vivienne RebelChief Science and Medical Officer
XRXavier Reveles
Xavier RevelesChief Operating Officer
TP
Timothy P. ZannesExecutive VP and Secretary
MDMichael Dougherty
Michael DoughertyChief Financial Officer2023–2024He has over 20 years of international finance experience, including roles involving financial planning, reporting, M&A, and work with PE-backed companies.
MH
Myron HolubiakNamed on SEC filing
BF
Barry FrankelNamed on SEC filing

Board

GR
Gary RubinBoard director
JP
Jamie PlattBoard director
PK
Peter KnightBoard director
SD
Stuart DiamondBoard director
RJ
Roby JoyceBoard director

Funding

SEC filings, press & company announcements

$8.4M disclosed across 4 of 9 rounds · 2017–2026

  • Undisclosed amountprivate placementAug 2026
    Source ↗
  • Undisclosed amountBest-Efforts OfferingJun 2026
    Source ↗
▶$4MofferedOct 2024 · 5 investors · Biotechnology
Rule 506(b)
Officers, directors & promoters on the filing
  • Stuart DiamondDirector
  • Vivienne RebelExecutive Officer
  • Xavier RevelesExecutive Officer
  • James EdwardsExecutive Officer
  • Robert AndersonDirector
  • Maria ZannesExecutive Officer, Director
  • Steven GirgentiExecutive Officer, Director
  • Roby JoyceDirector
  • Jamie PlattDirector
  • Peter S. KnightDirector
  • Gary RubinDirector
  • Timothy P. ZannesExecutive Officer
Offering amount
$4M
Sales commissions
$213K
Placement agents
Wallachbeth Capital LLC
First sale
Oct 2024
Incorporated
Corporation, Delaware
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶$450KraisedAug 2024 · 3 investors · Biotechnology
Rule 506(b)
Officers, directors & promoters on the filing
  • Gary RubinDirector
  • Maria ZannesExecutive Officer, Director
  • Roby JoyceDirector
  • Robert A. AndersonDirector
  • Jamie PlattDirector
  • Xavier RevelesExecutive Officer
  • Stuart DiamondDirector
  • Michael DoughertyExecutive Officer
  • Peter KnightDirector
  • Timothy P. ZannesExecutive Officer
  • Vivienne RebelExecutive Officer
  • Steven GirgentiDirector
Offering amount
$450K
Amount sold
$450K
Sales commissions
$36K
Placement agents
WallachBeth Capital LLC
First sale
Aug 2024
Incorporated
Corporation, Delaware
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶$1.3MraisedAug 2024 · 3 investors · Biotechnology
Rule 506(b)
Officers, directors & promoters on the filing
  • Vivienne RebelExecutive Officer
  • Gary RubinDirector
  • Xavier RevelesExecutive Officer, Director
  • Jamie PlattDirector
  • Maria ZannesExecutive Officer, Director
  • Peter KnightDirector
  • Stuart DiamondDirector
  • Roby JoyceDirector
  • Robert A. AndersonDirector
  • Steven GirgentiDirector
  • Timothy P. ZannesExecutive Officer
  • Michael DoughertyExecutive Officer
Offering amount
$1.3M
Amount sold
$1.3M
Sales commissions
$104.2K
Placement agents
WallachBeth Capital LLC
First sale
Aug 2024
Incorporated
Corporation, Delaware
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶$2.6MraisedMar 2024 · 3 investors · Biotechnology
Rule 506(b)
Officers, directors & promoters on the filing
  • Roby JoyceDirector
  • Maria ZannesExecutive Officer, Director
  • Vivienne RebelExecutive Officer
  • Michael DoughertyExecutive Officer
  • Jamie PlattDirector
  • Timothy P. ZannesExecutive Officer
  • Steven GirgentiExecutive Officer, Director
Offering amount
$2.6M
Amount sold
$2.6M
Minimum investment
$2.6M
Sales commissions
$225K
Placement agents
WallachBeth Capital LLC
First sale
Mar 2024
Incorporated
Corporation, Delaware
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶$4MraisedJul 2017 · 39 investors · Biotechnology
Rule 506(b)
Officers, directors & promoters on the filing
  • Myron HolubiakDirector
  • Barry FrankelDirector
  • Steven GirgentiDirector
  • Maria ZannesExecutive Officer, Director
  • Robert AndersonDirector
Offering amount
$4M
Amount sold
$4M
First sale
Jul 2017
Incorporated
Corporation, Delaware, 2014
Federal exemptions
06b
Full filing on SEC EDGAR ↗

Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.

Valuation · disclosed

Disclosed events
$9.1Mvaluation at IPOMay 2025 · $0.32/share · 424B4
filing ↗

Source: SEC prospectus filings, and round valuations the company or its investors disclosed — follow each entry's link for the claim.

Competitors · 2

by search overlap
Robinhood17 shared keywordsRobinhood is a financial trading platform that enables users to manage portfolios across stocks, ETFs, cryptocurrencies, options, futures, and prediction markets. The platform serves retail investors with low barriers to entry, offering portfolio management services and market insights.
StockTwits16 shared keywordsStocktwits operates an online community platform where investors and traders share ideas, analysis, and trade discussions organized around stock tickers. The page presented is its community guidelines rather than a product description.

Companies competing with bioAffinity Technologies for the same Google search keywords, organic and paid, via search-intersection analysis.

In the news

bioAffinity Technologies expands CyPath Lung federal distribution - The Globe and Mailtheglobeandmail.com · Aug 2026bioAffinity Technologies closes $4M private placement By Investing.cominvesting.com · Aug 2026bioAffinity Technologies Raises $3.2M in Best-Efforts Offering, Signs Purchase and Placement Pacts — TradingView Newstradingview.com · Jun 2026bioAffinity Technologies Reports Record $9.4 Million Revenue for 2024businesswire.com · Mar 2025

Frequently asked questions

What does bioAffinity Technologies do?
bioAffinity Technologies develops noninvasive laboratory diagnostic tests that use flow cytometry and machine learning analysis to detect early-stage lung cancer and other lung diseases from sputum samples. The company's lead product, CyPath® Lung, is offered through its subsidiary PPLS, a CAP-accredited clinical laboratory, and serves physicians evaluating patients at high risk for lung cancer.
Who founded bioAffinity Technologies?
bioAffinity Technologies was founded by Maria Zannes in 2014.
How much funding has bioAffinity Technologies raised?
bioAffinity Technologies has disclosed $8.4M raised across 4 of its 9 known rounds.
Where is bioAffinity Technologies headquartered?
bioAffinity Technologies is headquartered in San Anonio, US.